Elisabeth Schwartz | Senior Director, Investor Relations |
John Thero | President & CEO |
Mike Kalb | CFO |
Jessica Fye | JPMorgan |
Yasmeen Rahimi | ROTH Capital |
Ken Cacciatore | Cowen & co |
Louise Chen | Cantor Fitzgerald |
Michael Yee | Jefferies |
Welcome to Amarin Corporation’s Conference Call to discuss its Preliminary First Quarter Financial Results and Operational Update. This conference call is being recorded today, April 30, 2020.
I would now like to turn the conference over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of VASCEPA prescriptions, VASCEPA product and licensing revenues, costs and other commercial metrics and gross margin; our current plans and expectations regarding spending, including expenditures for the purchase of additional supply of VASCEPA; our current expectations regarding the adequacy of our financial resources ; our current plans and expectations for product revenue growth and product promotion in light of COVID-19 and any potential for added cardiovascular risk attention to VASCEPA as a result of COVID-19; our current plans and expectations regarding appealing the District Court VASCEPA related patent litigation decision to the Federal Circuit; and our current plans and expectations for a potential launch of generic versions of VASCEPA by generic companies and by ourselves, including expectations regarding ANDA approval by the FDA, generic cost effective supply availability, timing, potential levels of damages and ability to recover VASCEPA growth if the appeal succeeded; our current expectations for regulatory reviews outside the United States regarding VASCEPA approval and regulatory reviews inside the United States regarding consumer promotion and related timing thereof; our expectations regarding sales force productivity; our goals regarding the timing, scope, and success of international expansion including expectations regarding our ability to launch VASCEPA in Europe directly or through a potential partner; and our expectations for clinical trial results in China; and our current plans for commercial expansion in the United States, with and without entry of potential generic competition.